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a b s t r a c t
Methods that do not require animal sacriﬁce to detect botulinum neurotoxins (BoNTs) are critical for
BoNT antagonist discovery and the advancement of quantitative assays for biodefense and pharmaceutical applications. Here we describe the development and optimization of ﬂuorogenic reporters that detect
the proteolytic activity of BoNT/A, B, D, E, F, and G serotypes in real time with femtomolar to picomolar
sensitivity. Notably, the reporters can detect femtomolar concentrations of BoNT/A in 4 h and BoNT/E in
20 h, sensitivity that equals that of animal-based methods. The reporters can be used to determine the
speciﬁc activity of BoNT preparations with intra- and inter-assay coefﬁcients of variation of approximately 10%. Finally, we ﬁnd that the greater sensitivity of our reporters compared with those used in
other commercially available assays makes the former attractive candidates for high-throughput screening of BoNT antagonists.
Ó 2011 Elsevier Inc. All rights reserved.

Botulinum neurotoxins (BoNTs),1 produced by the bacteria of
the genus Clostridium, are the most lethal substances known. The
zinc-dependent endopeptidases act by entering neurons and cleaving soluble N-ethylmaleimide-sensitive factor attachment protein
receptors (SNAREs) and, thus, compromise the protein machinery
responsible for neurotransmitter release [1–8]. Failure to promptly
treat a victim of BoNT poisoning can result in ﬂaccid paralysis, respiratory failure, or death [9]. The combination of extreme potency and
a lack of medical treatments other than antitoxin administration and
intensive care has made BoNT a biodefense priority requiring the
discovery and development of assays to quantify toxins and to identify antagonists to counteract intoxication [10–13].
Despite their lethality, BoNTs are widely used for cosmetic and
pharmaceutical applications due in part to their exquisite speciﬁcity for the neuromuscular junction. BoNTs provide relief of muscle
tension and pain by inhibiting neurons that cause excessive muscle
contractions. Therapeutic preparations of BoNT/A and B serotypes
are Food and Drug Administration (FDA) approved for treating
⇑ Corresponding author. Fax: +1 608 441 8173.
E-mail address: wtucker@biosentinelpharma.com (W.C. Tucker).
Abbreviations used: BoNT, botulinum neurotoxin; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor; MS, mass spectrometry; CFP, cyan
ﬂuorescent protein; YFP, yellow ﬂuorescent protein; FRET, Förster resonance energy
transfer; HTS, high-throughput screening; PCR, polymerase chain reaction; FP,
ﬂuorescent protein; LB, Luria–Bertani broth; PBS, phosphate-buffered saline; IPTG,
isopropyl-b-D-thiogalactopyranoside; RT, room temperature; Ni-NTA, nickel–nitrilotriacetic acid; DTT, dithiothreitol; LOD, limit of detection; GFP, green ﬂuorescent
protein; SDS, sodium dodecyl sulfate; CV, coefﬁcient of variation.
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glabellar lines, strabismus, cervical dystonia, blepharospasm,
cranial nerve VII disorders, and primary axillary hyperhidrosis.
Dozens of ‘‘off-label’’ BoNT clinical applications have also been
documented [14–17].
The mouse bioassay, or lethality test, has been the standard for
testing BoNT-containing samples for the past 30 years [18–20].
Government agencies use this method for testing food and serum
samples for the presence of BoNT, whereas the pharmaceutical
industry uses it for quality control and to quantify ‘‘for human
use’’ BoNT preparations. The test is carried out by injecting mice
intraperitoneally with approximately 0.5 ml of sample per mouse
and recording the number of deaths over a 1- to 7-day period.
The assay is very sensitive, with a detection limit of 5–10 pg for
BoNT/A [21,22]. Results for the mouse bioassay are reported in
median lethal dose (LD50) units, where 1 LD50 is the amount of
BoNT required to kill 50% of injected mice after a deﬁned time
interval.
The mouse bioassay’s low-throughput methodology limits its
utility for BoNT antagonist development where small molecule library screening is impractical and could raise ethical concerns. Rapid and easily accessible assays that are not dependent on animal
use are required to meet biodefense diagnostic and therapeutic
needs. Furthermore, quality control proﬁles of BoNT-based drugs
require reliable non-animal-based tests to measure drug-speciﬁc
activity regardless of the manufacturer. Alternative methods that
rely on immunology, liquid chromatography, mass spectrometry
(MS), and ﬂuorescence methods to detect BoNT proteolytic activity
have emerged [23]. Notably, detection of multiple BoNT serotypes
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using a combination of immunological and MS methods has been
reported with mouse bioassay sensitivity and utility in complex
matrices such as serum and food products [24,25]. Drawbacks of
both MS and liquid chromatography methods are their limited
throughput and the requirement of expensive equipment. Fluorogenic methods offer a high-throughput alternative to either the
mouse bioassay or immuno-MS methods. However, most ﬂuorogenic assays use low-afﬁnity substrates, are more than four orders
of magnitude less sensitive than the mouse bioassay, and/or are
limited to only a few BoNT serotypes [26–31].
Dong and coworkers described two recombinant reporters containing residues 141–206 and 33–94 of neuronal SNARE proteins
SNAP-25 and synaptobrevin 2, respectively [32]. The substrates
were expressed as fusions of cyan and yellow ﬂuorescent proteins
(CFP and YFP, respectively), enabling the detection of BoNT proteolytic activity by Förster resonance energy transfer (FRET). The
ﬂuorogenic reporters were found to be sensitive to BoNT/A, B, E,
and F serotypes and able to detect picomolar concentrations of
the toxins in real time.
Here we report advances in the development and optimization
of FRET-based reporters that detect six of seven BoNT serotypes.
Through changes in the expression, puriﬁcation, and content of
the reporters, we were able to generate FRET-based reporters with
improved dynamic range and sensitivity. The resulting reporters
are robust in terms of reagent and assay stability, and they provide
sensitivity for BoNT not previously seen with ﬂuorogenic substrates. The FRET-based reporters are suitable for high-throughput
screening (HTS) for BoNT antagonists and for the development of
sensitive, real-time, and quantitative BoNT detection methods that
do not require animals.
Materials and methods
Materials and reagents
BoNT/A, B, D, and F serotypes, trypsin-treated BoNT/E, and trypsin-treated BoNT/G were provided by Metabiologics (Madison, WI,
USA).
Generation and expression of FRET-based reporters
The constructs pTrcHisA–CFP–SNAP25141–206–YFP and pTrcHisA–CFP–Syb233–94–YFP were provided by E.R. Chapman (University of Wisconsin–Madison) [32]. The constructs were engineered
to encode the 8-amino-acid StrepTagII sequence (WSHPQFEK) C
terminal of the YFP moiety using standard polymerase chain reaction (PCR) techniques [33]. The resulting constructs, pTrcHisA–
CFP–SNAP141–206–YFP–StrepTagII and pTrcHisA–CFP–Syb233–94–
YFP–StrepTagII, were further modiﬁed to incorporate Venus mutations into YFP using standard site-directed mutagenesis and
molecular biology techniques [34]. All resulting constructs encoded a protein with an N-terminal His6 tag, a C-terminal StrepTagII, a 4-amino-acid linker (GMAS) between the His6 tag and the
donor ﬂuorescent protein (FP), a 5-amino-acid linker (GGRSR) between the donor FP and the N terminus of SNAP25, a 6-amino-acid
linker (SNSGGS) between the C terminus of SNAP25 and the acceptor FP, and a 7-amino-acid linker (GIRSLAV) between the acceptor
FP and the StrepTagII.
Protein expression and puriﬁcation
All FRET reporter constructs were expressed in BL21 cells
(Novagen) and puriﬁed by double afﬁnity chromatography unless
otherwise indicated. Luria–Bertani broth (LB, 50 ml) supplemented
with 50 lg/ml carbenicillin was inoculated with a colony of BL21
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cells transformed with the indicated construct and grown overnight at 37 °C with shaking (250 rpm). Then 25 ml of the overnight
culture was transferred to 1 L of LB containing 50 lg/ml carbenicillin and grown to an OD600 of approximately 0.5 before induction of
protein expression by the addition of 0.4 mM isopropyl-b-D-thiogalactopyranoside (IPTG). The cultures were immediately transferred
to 25 °C unless otherwise indicated (see Fig. 1A) and grown with
shaking for an additional 7 h. Cells were harvested by centrifugation (8000g, 10 min), washed once with 30 ml of phosphate-buffered saline (PBS), and frozen at 80 °C.
Thawed cell pellets from 8-L cultures were resuspended with
240 ml of B-Per Protein Extraction Reagent (Pierce) supplemented
with 500 mM NaCl, 10 mM imidazole (pH 8.0), 6 kU of benzonase
(Novagen), 240 kU of lysozyme (Novagen), and Complete Protease
Inhibitor Cocktail (Roche). The cells were extracted for 20 min on a
rotating platter at room temperature (RT) before centrifugation at
25,000g for 20 min. The supernatant was then incubated with
64 ml of nickel–nitrilotriacetic acid (Ni-NTA)–Sepharose beads
(50% slurry, Qiagen) for 45 min with rotation at RT before centrifuging the beads at 500g for 3 min. The beads were washed three
times with 30 ml of wash buffer (50 mM Hepes–NaOH [pH 7.1],
500 mM NaCl, and 10 mM imidazole) and transferred to a 100-ml
column. The beads were washed with an additional 3 column volumes of wash buffer before elution of the protein in elution buffer
(50 mM Hepes–NaOH [pH 7.1], 500 mM NaCl, and 250 mM imidazole) and the collection of 5-ml fractions.
Peak fractions were pooled and further puriﬁed by StrepTag
afﬁnity chromatography on a Bio-Rad BioLogic fast protein liquid
chromatography (FPLC) system. His6-puriﬁed protein was injected
onto three 5-ml StrepTrap HP columns (IBA) plumbed in tandem
and equilibrated with 4 column volumes of wash buffer. Bound
protein was then washed with 4 column volumes of wash buffer
before eluting with 4–5 column volumes of 50 mM Hepes–NaOH
(pH 8.0), 150 mM NaCl, and 2.5 mM D-desthiobiotin in 1-ml factions. Peak fractions were pooled and dialyzed against 50 mM
Hepes–NaOH (pH 7.1), 10 mM NaCl, and 15% glycerol. The dialyzed
reporters were quantiﬁed by bicinchoninic acid (BCA, Pierce), aliquoted, and stored at 80 °C.
Fluorescence measurements, BoNT assays, and analysis
Fluorescence measurements were taken on a Varioskan spectral
scanning multimode microplate reader (Thermo Scientiﬁc). Reporter titrations and BoNT activity experiments were carried out in
100 ll of 50 mM Hepes–NaOH (pH 7.1), 5 mM NaCl, 0.1% Tween
20, 5 mM dithiothreitol (DTT), and 10 lM ZnCl2 in black, ﬂat-bottom, 96-well FluoroNunc plates (Nunc) unless otherwise indicated.
The reporter concentrations were maintained at 250 nM unless
otherwise indicated.
Data analysis was carried out with Prism 4.0 software (GraphPad Software). For all line graphs, data shown are averages from
triplicate determinations with bars indicating standard deviations.
Raw spectral scanning data and electropherogram images are representative data from at least three experiments. Limits of detection (LODs) were calculated by determining the minimal BoNT
concentration producing a signal more than 3 standard deviations
below control values in the absence of BoNT (n = 6).
Kinetics
The Michaelis constant (KM) and catalytic constant (kcat) were
determined by titrating a ﬁxed concentration of the indicated BoNT
serotype (62 nM, reduced with 5 mM DTT, 30 min) with 0.2–
50 lM of the indicated substrate (FRET reporter). Emission from
470 and 527 nm on 434 nm excitation was collected every 30–
60 s for at least 20 min. On completion of the kinetic reading,
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Fig.1. Optimization of BoTest™ reporters. (A) Optimization of bacterial expression temperature. The BoTest™ A/E reporter was expressed on IPTG induction, as described in
Materials and Methods, at 37 °C (solid line) or 25 °C (dashed line) and puriﬁed by Ni-NTA afﬁnity chromatography. The reporter (1 lM) was then excited at 434 nm, and the
emission spectra were collected from 450 to 550 nm. (B) Schematic of BoTest™ reporter constructs. The reporter constructs were expressed with an N-terminal His6 tag and a
C-terminal StrepTagII (ST) tag. syb, synaptobrevin 2. (C) More than 90% puriﬁcation of BoTest™ reporters. The BoTest™ A/E reporter was expressed and puriﬁed as described in
Materials and Methods. Sample purity was analyzed using an Experion Automated Electrophoresis System (Bio-Rad) according to the manufacturer’s directions. The
chromatograms show separations of the Ni-NTA afﬁnity-puriﬁed reporter (left) and the Ni-NTA StrepTagII double afﬁnity-puriﬁed reporter (right). Internal standards and
systems are indicated () and should not be taken into account when assessing purity. Insets show ﬂuorescence emission scans (Ex434nm/Em450–500nm) of the Ni-NTA afﬁnityor double afﬁnity-puriﬁed reporters. (D) Replacement of YFP with Venus reduces the salt sensitivity of the BoTest™ reporters. BoTest™ A/E reporters containing YFP (left) and
Venus (right) moieties were expressed and double afﬁnity puriﬁed. The reporters (1 lM) were incubated with the indicated NaCl concentrations, and ﬂuorescence emissions
were collected as described in panel A. For all emission scans, the CFP and FRET peaks are denoted by open and closed arrowheads, respectively.

remaining substrate was allowed to digest overnight following the
addition of excess BoNT (10 nm, BoNTs/A and E) or 100 lg/ml trypsin for 30 min (BoNTs/B, D, and F). Emission spectra were determined from the completely digested substrate.
Substrate disappearance was calculated at each time point and
for a particular substrate concentration using the equation (X –
neg)/(pos – neg), where X is the emission value (527/470) at a given time point, neg is the value in the absence of BoNT, and pos
is the value on the complete conversion of substrate into product.
Substrate disappearance at each substrate concentration was plotted as a function of time, and the linear range of substrate disappearance (<20% conversion) was ﬁtted by linear regression. The
slopes of the line or velocities (v) were then plotted as a function
of substrate concentration ([S]), and the data were ﬁtted by the
Michaelis–Menten equation, v = (Vmax  [S])/(Km + [S]), using Prism
software.

Results
Expression and puriﬁcation of FRET reporters
The recombinant FRET reporters described by Dong and
coworkers are composed of CFP and YFP connected by linkers containing residues 141–206 of SNAP-25 and 33–94 of synaptobrevin
2 [32]. The recombinant reporters have been named BoTest™ along

with the designation of A/E (BoTest™ A/E, CFP–SNAP–25141–206–
YFP) or B/D/F/G (BoTest™ B/D/F/G, CFP–Synaptobrevin233–94–YFP)
based on the speciﬁcity of their respective substrates for the different BoNT serotypes as described below. The CFP and YFP moieties
form a FRET pair where, in the intact reporter, CFP excitation leads
to YFP excitation by FRET, thereby quenching the ﬂuorescence
emission from CFP while increasing the ﬂuorescence emission
from YFP. Treating the reporter with BoNT leads to linker cleavage
and loss of FRET, thereby decreasing YFP emission and increasing
CFP emission. Cleavage of the reporters can be followed in real
time by measuring the ratio of YFP to CFP emission.
On initial characterization, we found that the BoTest™ reporters
as previously described suffered from low yields and low purity on
expression and puriﬁcation. In addition, the dynamic range of the
assay was limited by small changes in FRET ﬂuorescence on cleavage of the reporters by BoNT [32]. We addressed these problems by
examining the bacterial expression conditions for producing the
reporters and modifying the constructs to include alternative ﬂuorophores and additional afﬁnity puriﬁcation tags (Fig. 1). Reducing
the reporter bacterial expression temperature to 25 °C from 37 °C
resulted in a dramatic increase in FRET ﬂuorescence as judged by
an increase in ﬂuorescence emission at 526 nm, the ﬂuorescence
emission maximum for YFP (Fig. 1A). In addition, the drop in
expression temperature improved lot-to-lot reporter consistency
(data not shown). The increased FRET ﬂuorescence on reducing
the expression temperature likely reﬂects the poor folding and
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maturation characteristics of YFP at 37 °C [34]. Thus, the lowered
expression temperatures increased the proportion of reporter molecules that have functional ﬂuorescent proteins.
The full-length BoTest™ reporters copuriﬁed with lower molecular weight proteins on subjecting the protein extracts to Ni-NTA
afﬁnity chromatography, limiting the purity of the reporters to
60–70% (Fig. 1C). In an effort to eliminate these low-molecularweight proteins, we tested increasing the stringency of the afﬁnity
puriﬁcation, alternative bacterial expression cell lines, and a C-terminal His-tag version of the reporter, all to no avail (data not
shown). Therefore, we incorporated a second afﬁnity tag to allow
double afﬁnity puriﬁcation of the reporters, adding a StrepTagII
afﬁnity tag to the C terminus of the reporter (Fig. 1B) [33]. The
reporters were ﬁrst puriﬁed by Ni-NTA afﬁnity chromatography
via the N-terminal His6 tag and then subjected to StrepTactin afﬁnity chromatography, yielding high-purity BoTest™ reporters
(Fig. 1C). The BoTest™ A/E and BoTest™ B/D/F/G reporters are
now routinely puriﬁed to greater than 90% homogeneity. The double afﬁnity puriﬁcation scheme also increased the ratio of FRET
ﬂuorescence to CFP ﬂuorescence, indicating that some of the lower
molecular weight proteins were composed of truncated products
containing ﬂuorescent CFP but no or truncated YFP (Fig. 1C, insets).
The ﬁnal change to the reporters was the replacement of YFP
with the YFP derivative Venus. Venus differs from YFP by 5 amino
acid mutations that improve protein folding characteristics and reduce ﬂuorescence quenching by halide anions [34]. We found that
replacement of YFP with Venus reduced the reporter’s NaCl sensitivity, increasing the FRET emission of the reporters in the presence
of salt-containing buffers (Fig. 1D). The cumulative effects of the
expression, puriﬁcation, and ﬂuorophore changes resulted in
high-purity reporters with greatly improved FRET emission compared with the original reporters.
Reporter ﬂuorescence performance, signal linearity, and stability
The improved ﬂuorescence properties of the reporters increased
assay dynamic range. BoNT proteolytic activity produced a dramatic

decrease in FRET ﬂuorescence emission and a concurrent increase
in CFP emission (Fig. 2A). The ratio of FRET ﬂuorescence to CFP
ﬂuorescence dropped from approximately 2.5 in the absence of
BoNT to 0.6 in the presence of BoNT/A for the BoTest™ A/E reporter.
For the BoTest™ B/D/F/G reporter, the ratio dropped from approximately 3.6 in the absence of BoNT to 0.6 in the presence of BoNT/B.
The previous iteration of the reporters had a ratiometric (FRET
emission/CFP emission) value of approximately 0.75 in the absence
of BoNT and 0.55 in the presence of BoNT [32]. Thus, assay dynamic
range was improved approximately 10- to 15-fold on implementation of the changes described above.
BoNT reporters containing a single CFP moiety and single or
multiple YFP moieties were previously shown to exhibit nonlinear
ﬂuorescence emission characteristics on reporter dilution [29]. The
ratio of FRET ﬂuorescence emission to CFP ﬂuorescence increased
with increasing reporter concentrations, indicating that FRET
efﬁciency was concentration dependent. This effect may be due
to reporter dimerization at high nanomolar to micromolar concentrations where intermolecular FRET, in addition to concentrationindependent intramolecular FRET, contributes to the overall FRET
ﬂuorescence emission. Indeed, some green ﬂuorescent protein
(GFP) derivatives exhibit concentration-dependent dimerization
[35,36]. These nonlinear effects have consequences for assay precision because errors in reporter dilution can lead to changes in the
ratiometric value of the assay, thereby reducing accuracy. In addition, the change in ratiometric value in response to BoNT cleavage
or the interactions between BoNT and the reporter substrate may
be inﬂuenced by intermolecular reporter dimerization. Therefore,
we tested whether the BoTest™ reporters exhibited nonlinear concentration-dependent changes in ﬂuorescence emission.
We found that both the FRET and CFP ﬂuorescence emissions
increased in a linear fashion with increased BoTest™ A/E reporter
concentrations of up to 8 lM (Fig. 2B). The linear increases were
independent of whether or not the reporter was cleaved with
BoNT. Between 8 and 16 lM, there was a small nonlinearity in
both FRET and CFP emissions, likely due to inner ﬁlter effects; no
evidence of intermolecular FRET was seen [37]. Finally, reporter
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arrowheads, respectively. (B) Linearity of BoTest™ reporter ﬂuorescence responses. The BoTest™ A/E reporter was titrated (31.3 nm–16 lM) and incubated in the presence
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ratiometric values were concentration independent in the presence
and absence of BoNT, indicating that FRET efﬁciency is solely
dependent on the intramolecular interactions of the CFP and YFP
moieties (Fig. 2C). These data indicate that reporter ﬂuorescence
performance will not be subject to errors in reporter dilution. Similar results were seen with the BoTest™ B/D/F/G reporter (data not
shown).
The stability of BoTest™ reporters’ ﬂuorescence characteristics
and BoNT sensitivity was examined in response to prolonged storage at elevated temperatures and to freeze–thaw cycling (see Supplementary material). The reporters were found to be stable on
storage at RT (or 37 °C) for up to 7 days, as indicated by an absence
of loss in ﬂuorescence emission or BoNT sensitivity (see Suppl.
Fig. 1 in supplementary material). In addition, the reporters could
be freeze–thawed 10 times without loss in performance (Suppl.
Fig. 2). The data indicate that reporter CFP and Venus moieties
do not denature under the conditions examined and that the
reporters are stable and robust.
Sensitivity of BoTest™ reporters, time, and temperature dependence
The BoTest™ A/E reporter has the potential to detect the proteolytic activity of BoNTs/A, C, and E, whereas the BoTest™ B/D/F/G
reporter has the potential to detect the proteolytic activity of BoNTs/B, D, F, and G. We found that the BoTest™ A/E reporter was sensitive to BoNT/A holotoxin and trypsinized (nicked) BoNT/E (BoNT/
Etryp) holotoxin with detection of less than 10 pM of each toxin
possible within 1 h (Fig. 3). The sensitivity of the BoTest™ A/E reporter to BoNT/A was both time and temperature dependent
(Fig. 3, upper panels). At 37 °C, the reaction was largely complete
after 1 h, with very little additional cleavage seen even after 4 h.
At 25 or 30 °C, BoNT/A continued to cleave reporter for up to
20 h, with 300 fM toxin being detectable at both temperatures.
The temperature dependency of BoNT/A cleavage of the BoTest™
A/E reporter likely reﬂects the thermal stability of BoNT/A rather
than the stability of the reporter given that incubation of the reporter at 37 °C for up to 7 days does not affect the sensitivity of the reporter to BoNT/A (Suppl. Fig. 1). BoTest™ A/E reporter sensitivity to
BoNT/Etryp was time dependent but unaffected by temperature

Emission ratio
(Em 526/Em 470)

Emission ratio
(Em 526/Em 470)

25 ºC

variation between 25 and 37 °C (Fig. 3, lower panels). BoNT/Etryp
continued to cleave the reporter for up to 20 h at all temperatures
tested. BoNT/C holotoxin (up to 10 nm) did not cleave the BoTest™
A/E reporter (data not shown).
The BoTest™ B/D/F/G reporter detected the proteolytic activity
of BoNT/B, D, and F holotoxin and trypsin-treated BoNT/G with
varying sensitivities (Fig. 4). Picomolar quantities of BoNTs/B, D,
and F were detectable within 1–2 h of incubation at 37 °C, whereas
detection of picomolar quantities of BoNT/G required overnight
incubation.
Table 1 summarizes the LODs for the six detectable serotypes of
BoNT. Less than 30 pM of the six serotypes could be detected within a 20-h incubation, although the LODs varied considerably among
the serotypes. In addition, we found that LODs were dependent on
the lot of BoNTs tested and the degree of ‘‘nicking’’ that the BoNTs
undergo during expression. For example, the LODs for two lots of
BoNT/A varied 3- to 10-fold depending on the incubation temperature and time (Table 1). In addition, detection of BoNT/B could be
enhanced 3-fold by trypsin treatment of the toxin. Exogenous proteolytic nicking of certain clostridial toxins, notably serotypes B, D,
E, and F, is required to generate the fully active dichain form of
BoNT given that these toxins are only partially activated by endogenous proteases during bacterial expression [38–40]. These data
indicate that the BoTest™ LODs will be greatly affected by the
‘‘nicked’’ status of the BoNT preparations.
One mouse LD50 is estimated to be 4–20 pg of BoNT per injection depending on the serotype under consideration and the toxicity of the particular preparation of BoNT [21,22]. BoNTs/A and E
(300 fM) could be detected under optimal conditions, corresponding to approximately 4.5 pg of BoNT in the 100-ll reaction volume.
Thus, the mouse bioassay level of detection of BoNTs/A and E is
possible with the BoTest™ A/E reporter. BoNTs/Btryp and F (3 pM
or 45 pg) were detectable on extended 20-h incubations with
the BoTest™ B/D/F/G reporter, whereas more than 30 pM or
450 pg of BoNTs/D and G was detectable. Thus, the BoTest™ reporters are able to detect two serotypes (A and E) with mouse bioassay
sensitivity, two serotypes (B and F) within an order of magnitude of
bioassay sensitivity, and two serotypes (D and G) within two orders of magnitude of bioassay sensitivity.
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Fig.3. Incubation time and temperature dependency of BoTest™ A/E BoNT detection assay. The BoTest™ A/E reporter was incubated at the indicated temperatures with
varying concentrations of BoNT/A holotoxin (upper panels) or trypsin-treated BoNT/E (BoNT/Etryp) holotoxin (lower panels). After 1, 2, 4, and 20 h, the reporter was excited at
434 nm, and the emission was collected at 470 and 526 nm. The emission ratio (526/470) was plotted as a function of BoNT/A (upper panels) or BoNT/Etryp (lower panels)
concentration.
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Fig.4. Incubation time dependency of BoTest™ B/D/F/G BoNT detection assay. The
BoTest™ B/D/F/G reporter was incubated with varying concentrations of BoNT/B,
trypsin-treated BoNT/G (BoNT/Gtryp), BoNT/D, or BoNT/F holotoxin. After 1, 2, 4, and
20 h, the reporter was excited at 434 nm, and the emission was collected at 470 and
526 nm. The emission ratio (526/470) was plotted as a function of BoNT
concentration.

Real-time detection of substrate disappearance
A potential advantage of using a ratiometric ﬂuorescence readout to detect BoNT-dependent BoTest™ reporter cleavage is the
ability to directly correlate changes in the ratiometric value to
changes in substrate (intact reporter) concentration. Therefore,
we tested whether changes in the ratiometric ﬂuorescence value
on the addition of increasing BoNT/A concentrations yielded corresponding and proportional changes in intact BoTest™ reporter
(substrate) concentrations (Fig. 5). The BoTest™ A/E reporter was
titrated with BoNT/A, and the ratiometric value was determined
(Fig. 5A) immediately before adding sodium dodecyl sulfate
(SDS) buffer and analyzing the reaction for the presence of intact
BoTest™ reporter and cleavage products by automated electrophoresis (Fig. 5B). Intact reporter was clearly resolved from cleavage
products in electropherograms. Overlaying normalized ratiometric
values with the percentage intact reporter as a function of BoNT/A

concentration indicated that changes in the ratiometric ﬂuorescence
values were closely correlated with remaining intact reporter concentration (Fig. 5C). Finally, the normalized ratiometric values from
three independent runs were plotted against the amounts of intact
reporter remaining from the runs as determined by automated
electrophoresis (Fig. 5D). The data ﬁt demonstrates that the ratiometric value is highly dependent on the amount of remaining intact BoTest™ reporter, with a slope approaching unity
(0.97 ± 0.02, r2 = 0.99). Thus, substrate concentration can be followed in real time so long as the starting ratiometric value before
the addition of BoNT and the saturated ratiometric value in the
presence of excess BoNT are known.
The ability to easily determine the BoTest™ reporter (substrate)
concentration in real time allows the rapid and potentially accurate assessment of speciﬁc enzymatic activity from a given BoNT
preparation. We titrated the BoTest™ A/E reporter with BoNT/A
and measured the ratiometric ﬂuorescence value of the reporter
every 30 s to determined the BoNT/A preparation’s speciﬁc activity
(Fig. 6). The raw ratiometric ﬂuorescence values were normalized
and converted to substrate concentration (Fig. 6A). The initial
velocity of reaction at varying BoNT/A concentrations was then
determined by linear regression of the data points between 1
and 10 min (Fig. 6B). The initial velocity was then plotted as a function of BoNT/A concentration (Fig. 6C). The linear range of the plot
was ﬁtted again by regression, and speciﬁc activity was determined (in nM substrate cleaved min1 nM BoNT/A1). Finally, the
BoNT/A preparation’s speciﬁc activity was determined independently in three successive runs, with each experiment using independently diluted BoNT/A and reagents (Fig. 6D). The data show
that a BoNT/A preparation’s speciﬁc activity can be determined
with an intraassay coefﬁcient of variation (CV) of 9.0–10.5% and
an interassay CV of 9.5%. This is considerably more accurate than
the mouse bioassay, where CVs are typically on the order of 20–
40% depending on the methods and the number of mice used, with
the more accurate bioassay methods requiring more than 100 mice
for a single determination [20,41].
BoTest™ kinetic parameters
We determined the relative afﬁnities and catalytic efﬁciencies
of BoTest™ reporter cleavage by BoNT (Table 2). The Michaelis
constant (KM) values for BoTest™ A/E cleavage by BoNT/A and E
holotoxin were determined to be less than 1 lM, likely reﬂecting
the extensive BoNT/A and E binding elements contained within
the reporter [6,42]. Comparisons between kinetic parameters
determined by multiple laboratories are difﬁcult due to difference

Table 1
Limits of detection for the BoTest™ reporters.
Temperature (°C)

Time (h)

BoTest™ A/E

BoTest™ B/D/F/G

BoNT/A

BoNT/Etryp

BoNT/B

BoNT/Btryp

BoNT/D

BoNT/F

BoNT/Gtryp

1000
100
100
10

100
100
30
3

1000
1000
300
100

100
100
30
3

>10000
10000
1000
30

lot 1

lot 2

25

1
2
4
20

10
3
3
0.3

30
10
3
0.3

3
3
1
1

30

1
2
4
20

3
1
0.3
0.3

10
10
3
0.3

3
3
1
0.3

100
30
30
10

100
10
10
3

1000
300
300
100

100
100
30
3

>10000
300
300
30

37

1
2
4
20

3
3
3
ND

10
10
10
3

3
3
1
1

100
30
30
10

30
10
10
3

1000
300
300
30

100
30
30
10

>10000
300
300
30

Note: Values are in picomolars (pM) BoNT. ND, not determined.
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Fig.5. Changes in emission ratio correlate with the disappearance of intact BoTest™ reporter. The BoTest™ A/E reporter was incubated at 25 °C with varying concentrations of
BoNT/A holotoxin. After 2 h, the reporter was excited at 434 nm, and the emission was collected at 470 and 526 nm. Reactions were then immediately stopped in
electrophoresis buffer and analyzed using an Experion Automated Electrophoresis Station (Bio-Rad). (A) Sensitivity of the BoTest™ A/E assay to BoNT/A holotoxin. The
emission ratio (526/470) was plotted as a function of BoNT/A concentration. (B) Electropherogram of BoTest™ A/E reporter at varying BoNT/A concentrations. Shown are
samples treated with 0, 10, or 300 pM BoNT/A. Intact reporter is indicated by the open arrowhead, and cleavage products are indicated by the closed arrowheads. (C) Overlay
of normalized emission ratios and remaining intact reporter as a function of BoNT/A concentration. The data in panel A were normalized by setting the emission ratio of the
reporter in the absence of BoNT to 100 and the emission ratio of the reporter in the presence of saturating amounts of BoNT (1 nM) to 0. The percentage of intact BoTest™
reporter was determined by electrophoresis, as shown in panel B, and estimating the area of the peaks. (D) Loss of intact BoTest™ reporter is directly proportional to the
change in normalized emission ratios. Changes in normalized emission ratio were plotted as a function of remaining intact BoTest™ reporter and ﬁtted by linear regression.
Data are from three independent runs.
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Fig.6. Assessment of assay precision and enzymatic activity using BoTest™ A/E. 500 nM BoTest™ A/E reporter was incubated at 25 °C with varying concentrations of BoNT/A
holotoxin. At 30-s intervals for 60 min and at 15-min intervals thereafter, the reporter was excited at 434 nm, and the emission was collected at 470 and 526 nm. (A) Kinetics
of BoTest™ A/E reporter cleavage by BoNT/A. Left y axis: The emission ratio (526/470) for a given BoNT/A concentration was plotted as a function of time. Right y axis: The
emission ratios were normalized and then converted to substrate concentration by multiplying the normalized values by 500 nM (the initial concentration of BoTest™
reporter). (B) Early kinetics of substrate disappearance. Disappearance of the BoTest™ A/E reporter at 1 to 10 min was plotted as a function of time and ﬁtted by linear
regression. (C) Initial velocity as a function of BoNT/A concentration. The negative values of the slopes from the linear regression ﬁts in panel B were plotted as a function of
BoNT/A concentration. The linear velocity range of BoNT/A concentrations is shown in the inset and was ﬁtted by linear regression. The slope of the ﬁt gives speciﬁc activity of
the BoNT/A preparation (in nM substrate cleaved/min/pM BoNT/A). (D) Assay precision of BoTest™ A/E assay. Three independent determinations (runs) of a single preparation
of BoNT/A were made. Each intraassay CV was calculated by dividing the standard deviation of a single run by the average of the run. Each interassay CV was calculated by
dividing the standard deviation of the three runs by the average of the three runs.
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Table 2
Kinetic constants of BoTest™ reporter cleavage by BoNT.
BoTest™ A/E

KM (lM)
kCat (s1)
kCat/KM (lM1 s1)

BoTest™ B/D/F/G

BoNT/A

BoNT/Etryp

BoNT/B

BoNT/D

BoNT/F

0.67 ± 0.06
4.16 ± 0.28
6.18 ± 0.20

0.45 ± 0.16
14.6 ± 1.1
36.3 ± 16

15.9 ± 2.4
1.43 ± 0.72
0.11 ± 0.05

17.5 ± 2.0
0.30 ± 0.02
0.017 ± 0.002

8.50 ± 1.7
4.38 ± 0.53
0.58 ± 0.9

in the substrates, BoNT forms (e.g., light chain vs. holotoxin),
assays, and reaction conditions used. However, the KM values for
recombinant light chain cleavage of recombinant SNAP-25 were
previously determined to be 10–41 lM and 5–8 lM for BoNTs/A
and E, respectively [43–46]. The KM values determined for cleavage
of BoTest™ A/E are one order of magnitude lower, but again comparisons are limited by differences in assay parameters. Previous
determinations were carried out using an endpoint gel shift assay,
whereas we used a real-time kinetic approach. Regardless, these
results suggest that the BoTest™ A/E reporter binds to BoNTs/A
and E with high afﬁnity and is efﬁciently cleaved by the respective
proteases.
The KM values for the cleavage of BoTest™ B/D/F/G by BoNTs/B,
D, and F range from 8.5 to 17.5 lM. Similar values were reported
for cleavage of recombinant synaptobrevin (residues 1–96 or 1–
97) by the three serotypes using gel shift assays [47,48]. The KM
values for cleavage of BoTest™ B/D/F/G are more than 10 times
higher than the KM values for cleavage of BoTest™ A/E by BoNTs/
A and E. In addition, the catalytic efﬁciencies (kcat/KM) for BoNTs/
B, D, and F are one to three orders of magnitude lower than those
for BoNTs/A and E. Overall, the cleavage of BoTest™ B/D/F/G reporter occurs with lower afﬁnity and efﬁciency than the cleavage of
BoTest™ A/E reporter.
Comparisons with SNAPtide
BoNT antagonist development, and thus the development of
therapies, is hampered by the lack of high-throughput assays that
can replicate native BoNT–substrate interactions and can be used
in a cost-effective manner. SNAPtide (List Biological Laboratories)
is a ﬂuorogenic reporter for the detection of BoNT/A proteolytic
activity that has long been used to characterize BoNT–drug interactions or BoNT enzymatic activity [49–52]. This reporter consists of
a short peptide sequence with an internal donor/acceptor FRET
pair, with the acceptor acting as a quencher. Cleavage of the peptide results in an increase of ﬂuorescence emission due to loss of
donor quenching. The relatively short peptide sequence used in
SNAPtide, however, results in a substrate that must be used at high
concentrations due to its low afﬁnity for BoNT.
To determine whether BoTest™ provides a better alternative for
high-throughput applications, we compared SNAPtide and BoTest™
for their ability to detect BoNT/A proteolytic activity with statistical signiﬁcance (Fig. 7). BoTest™, as expected, could detect picomolar concentrations of BoNT/A, whereas SNAPtide provided little
detection below 1 nM BoNT (Fig. 7A). We next analyzed the data
for statistical signiﬁcance using Z0 factor calculations to assess assay dynamic range and data variation, with a Z0 factor value of
more than 0.5 signifying an acceptable assay for high-throughput
applications [53]. The BoTest™ assay gave Z0 factor values of more
than 0.5 at BoNT/A concentrations of 10 pM or above, whereas the
SNAPtide assay gave acceptable values at BoNT/A concentrations of
3 nM or above (Fig. 7B). The 300-fold difference in BoNT/A concentrations required to meet a common acceptance criterion for HTS
between BoTest™ and SNAPtide has implications for the cost of carrying out large-scale drug screening projects. The commercial
BoNT/A cost for a single 96-well plate is approximately US $0.07
at 10 pM and $21.62 at 3 nM; thus, for SNAPtide the cost of the en-

zyme (BoNT) will be one of the major considerations for HTS applications, whereas for BoTest™ the cost of enzyme will be of minimal
consideration.

Discussion
BoTest™ reporters have several advantages over existing BoNT
detection platforms. The reporters do not require animal sacriﬁce,
offer real-time capabilities, and do not require sophisticated equipment or extensive training to perform. They also offer a single
methodology for the detection of six of seven serotypes of BoNT,
the only technology to do so outside of MS- and high-performance
liquid chromatography (HPLC)-based platforms. Efforts to adapt
the reporters for BoNT/C, the only serotype not detected by these
reporters, are ongoing. Finally, these reporters are high-afﬁnity
BoNT substrates that offer picomolar to femtomolar sensitivity
depending on the serotypes of interest.
BoNT antagonist development has been largely limited to studies of small sets of compounds or peptides chosen through rational
design, computer-assisted, or other methods [54–59]. Although
these studies have provided a considerable amount of information
about BoNT catalytic mechanism and substrate requirements, few
of the small molecule inhibitors that have emerged from these
studies have sufﬁcient potency to be effective BoNT therapeutics.
Large-scale HTS efforts, the basis for most modern drug discovery,
are absent from BoNT antagonist development programs; thus, the
potential of the many small molecule and natural product libraries
found at public and private laboratories has been largely untapped.
Successful development of BoNT therapeutics could be accelerated
greatly if screens of more than 10,000 compounds were more commonplace and the information from those screens was shared
among biodefense laboratories.
A partial explanation for the lack of large-scale HTS efforts likely
resides in the lack of assays suitable for HTS. A variety of novel
BoNT detection platforms with varying sensitivities, serotype speciﬁcities, and mechanisms have been described [23]. However, few
platforms are suitable for HTS because many require multiple
detection steps to complete, lack sensitivity, or require equipment
that is too expensive or ill-suited for HTS applications. For example, many ﬂuorescent-based methods for the detection of BoNT/A
that rely on synthetic peptides often use short substrates with
low afﬁnity and low sensitivity [27,28,52]. The poor sensitivity requires that large quantities of BoNT be used to generate a suitable
signal, raising the cost of HTS to unacceptable levels (Fig. 7). Furthermore, the low-afﬁnity substrates limit the number and types
of inhibitors obtained from the screens. Ideally, HTS is carried
out with a substrate concentration at or near the KM value of the
enzyme to be screened to increase inhibitor mechanism diversity
[60]. Many ﬂuorescence-based reporters have reported KM values
of 100 lM or above; thus, high concentrations of reporter must
be used, further increasing the costs of HTS [28,52]. Short substrates also limit screens to active site inhibitors while ignoring
the potential of exploiting the strong binding interactions or
exosites that occur between BoNT and longer substrates, such as
the BoTest™ reporters, that are remote from the active site
[6,7,44,47,48,61–63].
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Fig.7. Comparison of BoTest™ A/E and SNAPtide reporters. BoTest™ A/E or SNAPtide reporter (6 lM) was incubated with varying concentrations of BoNT/A holotoxin for 4 h at
37 °C. (A) BoTest™ A/E and SNAPtide response to BoNT/A. The BoTest™ reporter was excited at 434 nm, and the emission was collected at 470 and 526 nm. The emission ratio
(526/470) was plotted as a function of BoNT/A concentration. The SNAPtide reporter was excited at 490 nm, and the ﬂuorescence emission was collected at 523 nm. The
relative ﬂuorescence units (RFU) value was plotted as a function of BoNT/A concentration. Averages and standard deviations are shown for 12 replicates. (B) Z0 factor
determinations at varying BoNT/A concentrations. For each BoNT/A concentration, a Z0 factor was calculated using the equation Z0 = 1  [3(rp+rn)]/|lp  ln|, where r is the
standard deviation, l is the mean, p is the positive control (signal in the presence of the indicated BoNT/A concentration), and n is the negative control (signal in the absence
of BoNT/A). BoNT cost per plate was based on a 96-well microtiter plate at 100 ll per well and the retail cost of a commercially available preparation of BoNT/A.

The detection methods described here meet the requirements
for HTS. First, the BoTest™ assays require only a single mix and read
step. Second, the BoTest™ assays are sensitive and meet common
criteria for acceptable HTS assay performance (Table 1 and
Fig. 7). Third, the reporters used in the assays react with BoNT with
low or sub-micromolar KM values, allowing cost-effective drug
testing using substrate concentrations at or near the KM value of
the reaction. Future studies done by our group or by laboratories
using the BoTest™ assays will fully realize the potential of the
reporters for BoNT inhibitor discovery.
A second area of advancements represented by these methods
is the ability to accurately quantify BoNT proteolytic activity from
six of seven serotypes with high sensitivity, relative ease, and
application-speciﬁc adaptability. The assays can be used in an endpoint fashion with femtomolar to picomolar sensitivity (Figs. 3 and
4), or they can be used to quantify enzyme-speciﬁc activity with
CVs of approximately 10% (Fig. 6). Ongoing work also shows that
the assays can be used in combination with immunological methods to measure the activity in complex matrices such as serum,
carrot juice, and whole blood (data not shown). With further adaptation, the BoTest™ assays should be applicable to a wide range of
environmental, biodefense, drug manufacturing, and pharmaceutical needs where high sensitivity detection of BoNT activity is
required.
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